Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Lonn E 1 , Bosch J 2 , Pogue J 2 , Avezum A 3 , Chazova I 4 , Dans A 5 Show all authors , Diaz R 6 , Fodor GJ 7 , Held C 8 , Jansky P 9 , Keltai M 10 , Keltai K 10 , Kunti K 11 , Kim JH 12 , Leiter L 13 , Lewis B 14 , Liu L 15 , Lopez-Jaramillo P 16 , Pais P 17 , Parkhomenko A 18 , Peters RJ 19 , Piegas LS 20 , Reid CM 21 , Sliwa K 22 , Toff WD 23 , Varigos J 21 , Xavier D 17 , Yusoff K 24 , Zhu J 25 , Dagenais G 26 , Yusuf S 27 , HOPE-3 Investigators

Affiliations 

  • 1 Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada. Electronic address: eva.lonn@phri.ca
  • 2 Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
  • 3 Dante Pazzanese Institute of Cardiology, São Paulo, Brazil
  • 4 Russian Cardiology Research Complex, Moscow, Russian Federation
  • 5 College of Medicine of the University of the Philippines, Manula, Philippines
  • 6 Fundacion ECLA, Rosario, Argentina
  • 7 University of Ottawa Heart Institute, Ottawa, Ontario, Canada
  • 8 Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • 9 University Hospital Motol, Prague, Czech Republic
  • 10 Hungarian Institute of Cardiology, Semmelweis University, Budapest, Hungary
  • 11 Diabetes Research Centre, University of Leicester, Leicester, United Kingdom
  • 12 St. Paul's Hospital, The Catholic University of Korea, Seoul, Korea
  • 13 Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
  • 14 Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
  • 15 Fu Wai Hospital, Chinese Academy of Medical Sciences, Beijing, China
  • 16 Fundacion Oftalmolgica de Santander (FOSCAL) and Instituto Masira, Medical School, Universidad de Santander, Bucaramanga, Colombia
  • 17 Division of Clinical Research and Training, St. John's Research Institute, Bangalore, India
  • 18 Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine
  • 19 Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
  • 20 Hospital do Coração, São Paulo, Brazil
  • 21 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
  • 22 Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, University of Cape Town and Soweto Cardiovascular Research Group, University of the Witwatersrand, Johannesburg, South Africa
  • 23 Department of Cardiovascular Sciences, University of Leicester and Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom
  • 24 Universiti Teknologi MARA, Selangor, Malaysia
  • 25 Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 26 Institut Universitaire de Cardiologie et Pneumologie de Québec, Université Laval, Québec, Canada
  • 27 Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
Can J Cardiol, 2016 Mar;32(3):311-8.
PMID: 26481083 DOI: 10.1016/j.cjca.2015.07.001

Abstract

Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications